Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor adjustment to its share capital following a repurchase of 3,200 H shares on 30 June 2026. The on-market transaction was executed at prices ranging from HKD 14.23 to HKD 14.50 per share, representing a volume-weighted average repurchase price of HKD 14.32. The aggregate consideration amounted to HKD 45,812.16.

The repurchased shares—equivalent to 0.0014% of Qyuns Therapeutics’ outstanding H shares—have been retained as treasury shares. Consequently, the company’s treasury stock balance increased to 3.69 million shares, while total issued shares remained unchanged at 227.07 million. Issued shares excluding treasury holdings now stand at 223.38 million.

The buyback was made under the general mandate approved on 29 May 2026, which authorises the company to repurchase up to 22.44 million shares. To date, 981,600 shares—0.44% of the issuer’s share capital at the mandate date—have been repurchased under this authority.

In accordance with Hong Kong listing rules, Qyuns Therapeutics is subject to a moratorium on issuing new shares or disposing of treasury shares until 30 July 2026.